India Pharma Outlook Team | Saturday, 08 March 2025
Lupin Ltd has rolled out the reviroxaban tablet, 2.5 mg, in the US market. This comes after the FDA gave its final nod to the company's abbreviated new drug application on March 7. The product matches the generic version of Xarelto 2.5 mg, which Janssen Pharmaceuticals Inc first created.
This medicine helps stop major heart problems in people with coronary artery diseases. It also prevents serious blood clot issues in those with peripheral artery diseases. This includes fewer surgeries needed for symptoms of peripheral artery diseases.
IQVIA MAT data through January 2025 shows that rivaroxaban tablets USP 2.5 mg are expected to bring in $446 million in yearly US sales. With this launch, Lupin will only further augment its position in the anticoagulant market.
The setting-in profit after tax for the company is at ?8,589 crore for the third quarter, which is up at 38.8% over ?6,187 crore in the comparable quarter of the previous year. Overall revenue from operations has also increased by 102.7%, standing at ?57,677 crore from ?51,974 crore a year before.
Lupin's EBITDA registered a Year on Year gain of 25 during this quarter, up from ?10,673 crore in third quarter a year ago to ?14,096 crore in Q3 of the fiscal year. The EBITDA margin for the company has also widened up from 21% in the December quarter a year ago to 21.1%. On the BSE, Lupin Ltd gained ?0.85 or 0.042% to close at ?2,020.30.
, CDSCO.jpg)
